Early use of tyrosine hydroxylase inhibitor metyrosine (MTR) or atrial natriuretic peptide (ANP) can prevent CRS caused by CD19 CAR-T cell infusion by reducing the production of catecholamines and various cytokines, without affecting the efficacy of CAR-T cells [77]. Here, TH is linked to congenital rubella syndrome.